W, R., V, C., AS, H., & MF, H. (2022). The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19. Dove Medical Press.
Chicago Style (17th ed.) CitationW, Rajabto, Chandika V, Harahap AS, and Ham MF. The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19. Dove Medical Press, 2022.
MLA (9th ed.) CitationW, Rajabto, et al. The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19. Dove Medical Press, 2022.
Warning: These citations may not always be 100% accurate.